Announcement of the Results

In response to the rapid tightening of global medical device regulations (especially the EU MDR), Manners Technology was the first to complete the comprehensive compliance upgrade of its Menchini liver biopsy needle product line in accordance with "EU Medical Device Regulation (MDR) 2017/745" and "US FDA 510(k) and De Novo pathways," and obtained the innovative medical device special approval from China NMPA. Its unique "clinical evaluation system based on real-world data (RWD)" was adopted as a demonstration case by the EU notified body. Through this system, the manufacturer successfully demonstrated the significant safety and performance improvement of its new generation product compared to the already marketed equivalent devices without conducting new traditional randomized controlled trials, and shortened the product launch cycle by at least 18 months.

Research and Development Background and Challenges

The Menchini needle, as a Class IIb (high-risk) active medical device, faces increasingly complex and differentiated regulatory barriers in major global markets:

  The severe challenge of the EU MDR: The MDR has abolished the previous self-declaration model and requires strict clinical evaluation for all Class IIb and above devices, and has imposed nearly stringent requirements for "equivalence" proof. Many products certified under the old directive (MDD) are at risk of being withdrawn from the market.

  High cost of evidence generation: For mature technologies like biopsy needles, conducting a prospective, randomized controlled clinical trial to prove their "advantages" is both expensive, time-consuming, and ethically challenging (for example, it is difficult to use older and potentially inferior needle devices for the control group patients).

  Fragmentation of global market access: Regulations, technical document formats, and quality management systems (such as QSR vs. ISO 13485) vary in the United States, Europe, China, Japan, etc., and enterprises need to invest significant resources in repetitive registration work.

   Post-market regulatory (PMCF) pressure: Both the MDR and FDA require the establishment of an active post-market clinical follow-up plan to continuously collect safety and performance data, which places high demands on the long-term resource investment of enterprises.

Core Technological Innovation

The manufacturer has transformed regulatory compliance from a "cost center" to a "strategic capability," and has achieved three major innovations:

  Prospective Real-World Data Registration Platform: Several years ago, manufacturers had already collaborated with over 100 liver disease centers worldwide to establish the "Mengchin Needle Clinical Application and Outcome Registration Research Network." In routine clinical use, anonymized data of each biopsy case were collected prospectively and structurally, including patient baseline characteristics, operational details, needle model, sample quality, immediate and long-term complications, etc. These data underwent strict data governance and quality control, forming a large-scale high-quality real-world evidence database.

  Modular General Technical Documentation and Difference Analysis Engine: An intelligent document management system was developed, integrating the core modules of product general safety and performance requirements (GSPR), risk analysis reports, verification test reports, etc. According to the requirements of different regulatory agencies, the system can automatically identify differences and generate difference analysis reports and supplementary material lists in accordance with local formats, significantly improving the efficiency and consistency of registration materials preparation.

  AI-based Post-Market Alert System: Using natural language processing technology, the system automatically scans global major regulatory agency databases, medical literature databases, social media, and news 24/7, searching for adverse event reports, safety alerts, or potential risk signals related to liver biopsies or similar devices. The system can automatically perform preliminary classification, severity assessment, and early warnings, enabling the company to identify and respond to potential risks earlier than competitors.

Mechanism of Action

These compliance innovations address regulatory challenges through "evidence paradigm shift" and "process digitization":

  The leverage of real-world evidence: Under the MDR framework, when the "equivalence" path cannot be used, the prospective collection of RWD can serve as the main evidence for clinical evaluation. Manufacturers utilize the data from their registration study networks and employ advanced statistical methods such as propensity score matching to prove that their new generation of needles significantly outperform the matching cohort using the old models in multiple key endpoints such as sample sufficiency rate, operation time, and patient pain score. This circumvents the costly and time-consuming RCT.

  Intelligent differential analysis: By codifying global regulatory requirements, the system can automatically compare new and old products, as well as the similarities and differences in requirements across different regions. For instance, the FDA may pay more attention to the risk control of incorrect labeling and usage, while the EU MDR emphasizes the quantitative demonstration of the clinical benefit-risk ratio. The system can precisely identify the key points that require supplementary evidence or document revisions.

  Proactive risk management: The AI alert system has changed the traditional passive mode of receiving adverse event reports. It can discover "signals" from massive unstructured information that have not yet formed formal reports but may indicate potential problems, such as a paper mentioning a rare complication related to a specific operation technique. This enables manufacturers to actively update product instructions, release doctor education materials, and even initiate targeted post-market studies, demonstrating the highest responsibility standard.

Efficacy Verification

Take the case where the manufacturer successfully completed the EU MDR clinical evaluation through RWE as an example:

  Data volume and quality: The registration research network has cumulatively collected over 15,000 biopsy cases using its new-generation syringes, with data completeness exceeding 97%, and has been audited by an independent statistician appointed by the certification body.

  Regulatory approval: Based on these RWE, the manufacturer's clinical evaluation report and regular safety update report were all approved by the EU certification body in one go. This case was included in the guidelines of the EU Medical Devices Coordination Group as an example of using RWE to support device upgrades.

  Business value: Through this approach, this new product entered the European market 20 months earlier than originally planned (if a new RCT had been conducted), seizing the competitive advantage and saving several hundred million euros in direct R&D costs.

Research and Development Strategy and Philosophy

Manners Technology's regulatory strategy is "Compliance drives research and development, evidence creates value." They view regulatory requirements as "design inputs" for product development, rather than a "checklist" for post-event compliance. During the product concept stage, the regulatory team works closely with the R&D team to ensure that the design verification and risk control measures of the product directly align with the highest requirements of MDR and FDA. The philosophy is: The most efficient compliance is to build an unassailable evidence chain during the research and development process. They actively participate in pre-submission meetings and scientific consultations with regulatory agencies to ensure that the research direction is consistent with regulatory expectations and minimize uncertainty.

Future Outlook

In the future, regulatory compliance will be deeply integrated with "digital twins" and "value-based healthcare." Manufacturers are exploring the establishment of "virtual clinical evaluation models" for their products: using massive data collected from the real world and laboratories to build computer models that simulate the effects of the products when used by virtual populations. This "silicon-based trial" can be used to predict rare adverse events, evaluate the benefit-risk ratio in different subgroups, and serve as a supplement to traditional clinical evaluations. At the same time, with the rise of the pay-for-effectiveness model, manufacturers need to prove that their products not only "work" but also can improve patients' long-term outcomes and reduce overall healthcare costs. Therefore, future clinical evidence will not only include technical success rates and complication rates, but also cover the rate of treatment changes resulting from improved diagnostic accuracy, as well as the savings in unnecessary surgeries or delayed treatments due to the avoidance of unnecessary procedures. Manufacturers are transforming from "device suppliers" to "health outcome partners," and strong regulatory and evidence capabilities are the cornerstone of this transformation.